alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 1–21 of 21 studies with an author at University of Newcastle Australia (AU) · free to read · 27,380 in the whole library · How the 0–100 score works

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Projections of multi-morbidity in the older population in England to 2035: estimates from the Population Ageing and Care Simulation (PACSim) model

✓ Peer-reviewed alzhub usefulness score 72 out of 100. Age and ageing 2018-05-01

Little is known on how risk factors of younger cohorts will play out in the future burden of multi-morbidity (two or more concurrent long-term conditions). 2 key findings →

Design: longitudinal study Participants: 303,589 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

An Internet-Based Intervention Augmented With a Diet and Physical Activity Consultation to Decrease the Risk of Dementia in At-Risk Adults in a Primary Care Setting: Pragmatic Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 68 out of 100. Journal of medical Internet research 2020-09-24

Baseline assessments were conducted on 128 participants. 3 key findings →

Design: randomized controlled trial Participants: 125 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Combining modifiable risk factors and risk of dementia: a systematic review and meta-analysis

✓ Peer-reviewed alzhub usefulness score 68 out of 100. BMJ open 2019-01-25

The strength of the reported associations, the consistency across studies and the suggestion of a dose response supports a need to keep modifiable risk factor exposure to a minimum and to avoid exposure to additional modifiable risks. 3 key findings →

Design: systematic review Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Childhood Lifestyle Behaviors and Mental Health Symptoms in Adolescence

✓ Peer-reviewed alzhub usefulness score 60 out of 100. JAMA Network Open 2025-02-14

Altogether, 187 adolescents (97 boys [51.9%]; mean age, 15.8 [0.4] years) had valid data on self-reported lifestyle behaviors, and 170 adolescents had valid data on device-assessed lifestyle behaviors. 5 key findings →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Potentially Inappropriate Prescribing in Australian Nursing Home Residents with Advanced Dementia: A Substudy of the IDEAL Study

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of palliative medicine 2018-08-14

Use of potentially inappropriate medications in Australian nursing home residents with advanced dementia is common. 3 key findings →

Design: randomized controlled trial Participants: 65 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Diet Quality Indices, All-Cause Mortality, Cardiovascular Disease, and Dementia—Outcomes from the Australian Longitudinal Study on Women’s Health

✓ Peer-reviewed alzhub usefulness score 55 out of 100. Journal of Nutrition 2025-04-03

There were 656 deaths, 1585 incidents of CVD and 165 dementia diagnoses during 17.2 years of follow-up. 5 key findings →

Design: longitudinal study Participants: 9,584 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

The Medical Genome Reference Bank contains whole genome and phenotype data of 2570 healthy elderly

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Nature communications 2020-01-23

Population health research is increasingly focused on the genetic determinants of healthy ageing, but there is no public resource of whole genome sequences and phenotype data from healthy elderly individuals. 4 key findings →

Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Benefits of exercise training on cerebrovascular and cognitive function in ageing

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2020-09-20

Derangements in cerebrovascular structure and function can impair cognitive performance throughout ageing and in cardiometabolic disease states, thus increasing dementia risk. 2 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cerebral glucose metabolism and cognition in newly diagnosed Parkinson's disease: ICICLE-PD study

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry 2016-10-06

FDG-PET was performed on a cohort of 79 patients with newly diagnosed PD (mean disease duration 8 months) and 20 unrelated controls. 4 key findings →

Participants: 79 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Interpreter Communication Quality in Cognitive Assessments for Dementia

✓ Peer-reviewed alzhub usefulness score 52 out of 100. JAMA Network Open 2025-02-12

At baseline, there were 126 participants (106 [84.1%] women); mean (SD) age was 44.13 (12.71) years, mean years of interpreting experience was 8.57 (8.48) years, and 106 of 120 (88.3%) lived in an urban area. 5 key findings →

Participants: 126 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Targeting innate immunity for neurodegenerative disorders of the central nervous system

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neurochemistry 2016-09-01

Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying dementia risk profiles for targeted interventions: A latent class analysis of at‐risk middle‐aged Australians

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Alzheimer s & Dementia 2025-11-01

Among 403 participants (mean age 56.4 ± 5.7 years, 62.5% female), the median number of dementia risk factors was 5.0; hyperlipidaemia (92.5%), low cognitive activity (72.5%), obesity (57.6%), and hypertension (52.7%) were the most prevalent. 5 key findings →

Design: cross-sectional Participants: 403 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed